Experience Driven, Discovery Focused
Focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor.
- First approved in Japan 2013 and then by the FDA November 2019 for Parkinson’s Disease.
- The only approved A2a antagonist.
- Japan ONLY sales in 2019 –> $1B USD
A2a Receptor: A Validated Target
Multiple studies have shown that that A2a Receptor shows the great promise as the key to unlock many different types of diseases.
Proven Players, Focused on True Discovery while Maximizing Capital.
Proven Proprietary Compounds
Total Market Value